Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
563 stopped studies mapped to Malignant Pancreatic Neoplasm and descendants · 93% state a reason
Over the 563 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT03472833 | High-dose Vitamin D3 in Pancreas Cancer(VITdCUT) | Phase 3 | terminated | Mar 21, 2018 | Medical University of Graz | slow recruitment, patients lost to follow-up due to Covid-19 pandemic. | COVID-19 / pandemic |
| NCT02628535 | Safety Study of MGD009 in B7-H3-expressing Tumors | Phase 1 | terminated | Dec 11, 2015 | MacroGenics | Business decision (not for safety reasons) | Safety / toxicity |
| NCT05181865 | Phase 1/2a Study to Evaluate FL-301 in Patients With Advanced Solid Tumors | Phase 1 / Phase 2 | withdrawn | Jan 6, 2022 | Flame Biosciences | Sponsor Decision | Sponsor / business decision |
| NCT01445327 | Predictors of Tumor Response and of Radiation Therapy Side Effects in Patients With… | — | terminated | Oct 3, 2011 | National Cancer Institute (NCI) | Slow, insufficient accrual. | Enrollment / accrual |
| NCT03637491 | A Study of Avelumab, Binimetinib and Talazoparib in Patients With Locally Advanced or… | Phase 1 / Phase 2 | terminated | Aug 20, 2018 | Pfizer | Available clinical data has shown limited anti-tumor activity and reaching target study drug dose… | Other (stated, no rule matched) |
| NCT03331640 | A Health Service Research Study to Investigate Survival of Metastatic Pancreatic Cancer…(PANTHEON) | Phase 2 | terminated | Nov 6, 2017 | AIO-Studien-gGmbH | slow recruitment | Enrollment / accrual |
| NCT03757455 | ERAS Protocol in Pancreaticoduodenectomy and Total Pancreatectomy | N/A | terminated | Nov 29, 2018 | Tampere University Hospital | Not enought participants | Other (stated, no rule matched) |
| NCT04105062 | LS301 Uptake in Tumors of Patients Undergoing Liver, Pancreas, or Gastric Surgery | Phase 1 / Phase 2 | withdrawn | Sep 26, 2019 | Washington University School of Medicine | One of the investigators is leaving the University. | Other (stated, no rule matched) |
| NCT04070313 | A Phase II Study of S-1 Adjuvant Chemotherapy in Patients With Resected Pancreatic Cancer… | Phase 2 | terminated | Aug 28, 2019 | TTY Biopharm | Study treatment is to use TS-1 (mono-chemotherapy agent) in adjuvant setting for pancreatic cancer,… | Other (stated, no rule matched) |
| NCT03407040 | Generation of Cancer Antigen-Specific T-cells From Human Induced Pluripotent Stem Cells… | — | terminated | Jan 23, 2018 | National Cancer Institute (NCI) | Investigator left NIH | Investigator |
| NCT03599362 | Study of Nivolumab, Cabiralizumab, and Stereotactic Body Radiotherapy (SBRT) for Locally… | Phase 2 | terminated | Jul 26, 2018 | NYU Langone Health | PI departure from institution | Other (stated, no rule matched) |
| NCT04311047 | Preoperative Detection of Lymph Node Metastases in Pancreatic and Periampullary Carcinoma…(NANO-PANC) | N/A | terminated | Mar 17, 2020 | Radboud University Medical Center | We decided to stop inclusions and start analysis after 26 inclusions. | Other (stated, no rule matched) |
| NCT02687230 | Phase 1 Imaging Study of 89Zr-DFO-HuMab-5B1 With HuMab-5B1 | Phase 1 | terminated | Feb 22, 2016 | BioNTech Research & Development, Inc. | Sponsor decision | Sponsor / business decision |
| NCT01510561 | A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients… | Phase 1 | withdrawn | Jan 16, 2012 | Gilead Sciences | no subjects enrolled | Enrollment / accrual |
| NCT01956812 | Phase 3 Trial of 90Y-Clivatuzumab Tetraxetan & Gemcitabine vs Placebo & Gemcitabine in…(PANCRIT®-1) | Phase 3 | terminated | Oct 8, 2013 | Gilead Sciences | The DSMB conducted an interim analysis on overall survival, which showed that the treatment arm did… | Efficacy / futility |
| NCT01683422 | Chemotherapy Plus Proton-chemotherapy for Locally Advanced Pancreatic Cancer | N/A | terminated | Sep 11, 2012 | Loma Linda University | Updated chemotherapy regimens currently evaluated in clinical trials due to lack of progress in… | Other (stated, no rule matched) |
| NCT01335945 | Safety and Efficacy of Cryoablation for Abdominal Pain Associated With Pancreatic Cancer | Phase 1 | terminated | Apr 15, 2011 | Boston Scientific Corporation | Low enrollment \& subjects didn't survive to study end due to cancer progression. | Enrollment / accrual |
| NCT02908451 | A Study of AbGn-107 in Patients With Gastric, Colorectal, Pancreatic or Biliary Cancer | Phase 1 | terminated | Sep 21, 2016 | AbGenomics B.V Taiwan Branch | COVID-19 pandemic has caused a huge operational difficulty for this ongoing clinical trial, as many… | COVID-19 / pandemic |
| NCT03117556 | Bilateral Thoracoscopic Splanchnicectomy for Pain Relief in Patients With Unresectable… | N/A | withdrawn | Apr 18, 2017 | University of Louisville | no subjects enrolled | Enrollment / accrual |
| NCT03451773 | M7824 (MSB0011359C) in Combination With Gemcitabine in Adults With Previously Treated… | Phase 1 / Phase 2 | terminated | Mar 2, 2018 | National Cancer Institute (NCI) | Study was closed after one treatment related death. | Other (stated, no rule matched) |
| NCT04270929 | Pressure Enabled Drug Delivery By Pancreatic Retrograde Venous Infusion For Advanced…(PANC-001) | Phase 1 | withdrawn | Feb 17, 2020 | Roger Williams Medical Center | Insufficient accrual rate | Enrollment / accrual |
| NCT03536182 | Trial of Carbon Ion Versus Photon Radiotherapy for Locally Advanced, Unresectable…(CIPHER) | Phase 3 | withdrawn | May 24, 2018 | University of Texas Southwestern Medical Center | Due to COVID and other recruitment issues the trial could not be initiated. | COVID-19 / pandemic |
| NCT03358095 | Cancer of the Head of the Pancreas: Early Surgery or Preoperative Biliary Drainage? | N/A | withdrawn | Nov 30, 2017 | Helsinki University Central Hospital | Investigators busy with other projects at the moment. | Other (stated, no rule matched) |
| NCT03350763 | Biliary Drainage Preceding Possible Pancreaticoduodenectomy. Are Self-expandable Metallic… | N/A | withdrawn | Nov 22, 2017 | Helsinki University Central Hospital | Investigators busy with other projects at the moment | Other (stated, no rule matched) |
| NCT04464967 | Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in… | Phase 1 / Phase 2 | withdrawn | Jul 9, 2020 | NKGen Biotech, Inc. | Trial not initiated | Other (stated, no rule matched) |
| NCT04083651 | A Study of Methylnaltrexone Bromide (MNTX) in Participants With Advanced Pancreatic Cancer | Phase 2 / Phase 3 | withdrawn | Sep 10, 2019 | Bausch Health Americas, Inc. | Due to pandemic challenges and consideration of a different study design in the future. | COVID-19 / pandemic |
| NCT04151719 | An Extension Study of Methylnaltrexone Bromide (MNTX) in Participants With Advanced… | Phase 3 | withdrawn | Nov 5, 2019 | Bausch Health Americas, Inc. | Due to pandemic challenges and consideration of a different study design in the future. | COVID-19 / pandemic |
| NCT02608229 | BVD-523 Plus Nab-paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Cancer | Phase 1 | terminated | Nov 18, 2015 | Washington University School of Medicine | Adverse events | Safety / toxicity |
| NCT03137706 | Characterization of Mechanical Tissue Properties in Patients With Pancreatic, Liver, or… | — | terminated | May 3, 2017 | University of Southern California | Insufficient accrual | Enrollment / accrual |
| NCT03536208 | Biological Effect of Warfarin on Pancreatic Cancer | Early Phase 1 | withdrawn | May 24, 2018 | University of Texas Southwestern Medical Center | no accrual for over 12 months | Enrollment / accrual |
| NCT03649035 | Eus-guided Cryothermal Ablation in Stage III Pancreatic Adenocarcinoma | Phase 3 | withdrawn | Aug 28, 2018 | Istituto Clinico Humanitas | Stopped for internal decisions | Other (stated, no rule matched) |
| NCT02985801 | PERT for Treatment of Exocrine Pancreatic Insufficiency in Patients With Unresectable… | Phase 1 / Phase 2 | terminated | Dec 7, 2016 | Massimo Raimondo, M.D. | Study was terminated due to difficulty in recruiting subjects. | Enrollment / accrual |
| NCT01206296 | Adjuvant Intraperitoneal Gemcitabine for Resectable Pancreatic Adenocarcinoma | Phase 2 | terminated | Sep 21, 2010 | Medstar Health Research Institute | Study suspended | Other (stated, no rule matched) |
| NCT00066677 | Bevacizumab With or Without Docetaxel in Treating Patients With Previously Treated… | Phase 2 | terminated | Aug 7, 2003 | Fox Chase Cancer Center | Stopped accordining to early stopping rule for futility | Efficacy / futility |
| NCT03244683 | A Study of the Efficacy of ONS to Reduce Postoperative Complications Associated With…(INSPIRE) | N/A | terminated | Aug 9, 2017 | Ohio State University | Closed due to low enrollment | Enrollment / accrual |
| NCT03718650 | Total Tumor Mapping (TTM) for Resectable Pancreatic Cancer | Early Phase 1 | withdrawn | Oct 24, 2018 | H. Lee Moffitt Cancer Center and Research Institute | Lack of funding | Funding |
| NCT02921737 | TAS-102 (Lonsurf) in Metastatic or Locally Advanced Unresectable Pancreatic… | Phase 2 | terminated | Oct 3, 2016 | University of Florida | insufficient time to accrue sufficient subjects before end of funding | Enrollment / accrual |
| NCT03760614 | A Study of Entinostat and FOLFOX in Subjects With Pancreatic Adenocarcinoma | Phase 1 | withdrawn | Nov 30, 2018 | Abramson Cancer Center at Penn Medicine | Lack of Funding | Funding |
| NCT03585062 | Trial of Neoadjuvant Chemotherapy With S1 Plus Paclitaxel-albumin on Pancreatic Cancer | Phase 2 | terminated | Jul 12, 2018 | Zhejiang Provincial People's Hospital | The paclitaxel-albumin halt production. | Other (stated, no rule matched) |
| NCT00003531 | Antineoplaston Therapy in Treating Patients With Stage IV Pancreatic Cancer | Phase 2 | terminated | Jan 27, 2003 | Burzynski Research Institute | Slow accrual | Enrollment / accrual |
| NCT04034745 | Open Label Study to Analyze the Effect of Telotristat Ethyl on Weight Regulation/Gain | — | withdrawn | Jul 26, 2019 | Andrew Hendifar, MD | lack of funding | Funding |
| NCT03563352 | Nutritional Preferences and Product Accessibility in Oral Nutritional Supplements in… | — | withdrawn | Jun 20, 2018 | University of Southern California | Zero accrual | Enrollment / accrual |
| NCT01562899 | A Study of MEK162 and AMG 479 in Patients With Selected Solid Tumors | Phase 1 / Phase 2 | terminated | Mar 26, 2012 | Pfizer | Study was withdrawn due to scientific and business considerations. | Sponsor / business decision |
| NCT03042780 | FOLFIRINOX in Metastatic High Grade Gastroenteropancreatic Neuroendocrine Carcinomas | Phase 2 | terminated | Feb 3, 2017 | H. Lee Moffitt Cancer Center and Research Institute | Slow accrual | Enrollment / accrual |
| NCT04262388 | A Multi-Cancer, Multi-State, Platform Study of Durvalumab (MEDI4736) and Oleclumab…(DOME) | Phase 2 | withdrawn | Feb 10, 2020 | University Health Network, Toronto | Overall clinical activity (ORR) for oleclumab + durvalumab is minimal across tumor types and does… | Other (stated, no rule matched) |
| NCT01938716 | Gemcitabine Pharmacokinetics After Preoperative Chemoradiation Therapy | N/A | terminated | Sep 10, 2013 | M.D. Anderson Cancer Center | Early termination due to low accrual | Enrollment / accrual |
| NCT02757391 | CD8+ T Cell Therapy and Pembrolizumab in Treating Patients With Metastatic… | Phase 1 | terminated | May 2, 2016 | M.D. Anderson Cancer Center | Study halted prematurely and will not resume; participants are no longer being examined or… | Other (stated, no rule matched) |
| NCT02919553 | Modified Wet Suction Versus Capillary Techniques for EUS Guided Fine Needle Aspiration… | N/A | withdrawn | Sep 29, 2016 | Loma Linda University | decided not to proceed with study at this time | Other (stated, no rule matched) |
| NCT03509298 | Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced… | Phase 2 | withdrawn | Apr 26, 2018 | Fuda Cancer Hospital, Guangzhou | No participants enrolled | Enrollment / accrual |
| NCT00493441 | AVN944 in Combination With Gemcitabine for the Treatment of Pancreatic Cancer | Phase 2 | terminated | Jun 28, 2007 | Vertex Pharmaceuticals Incorporated | not stated | Not stated |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Feb 15, 2022source: clinicaltrials